Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

Abstract

Rituximab appears to be well tolerated and may have potential efficacy for skin disease in dc-SSc.

Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

“…(1)(2)(3) Our study, however, was the only one specifically designed to test the effect of RTX on SSc-associated ILD, since the presence of ILD was an inclusion criterion and most patients had severe ILD. On the contrary the other two studies excluded patients with severe ILD and only a fraction of patients had evidence of mild ILD.…”

Molecular Mechanisms of Scleroderma and Fibrosis

“…Figure 2 shows some cytokines related to systemic sclerosis and fibrosis, cellular sources of growth factors and biological activities (36-48). (36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48) …”

Recent Advances in Systemic Scleroderma in Childhood

“…The role of rituximab in ILD is mentioned above, but further studies are in progress to determine whether it has other beneficial effects. B-cell targeted therapies are emerging [112][113][114]. Interferon type 1, which may also play a role in SSc pathogenesis, might be targeted later on [115].…”